Tumor cells with these alterations were assessed for gliomasphere growth at 4 weeks post-sgRNA transduction—loss of each of these genes led to significantly increased gliomasphere proliferation (Tead2-loss—6.44x, Nav3-loss—5.04x, Spred1-loss—3.58x, relative cell viability compared with non-targeting sgRNA control (1x); p < 0.0001, < 0.0001, and 0.036 respectively, adjusted one-way ANOVA test, 3D, CellTiter-Glo 3D cell viability assay, Fig. 8d, e, Additional file 1: Fig. S27b, c, Additional file 12: Table S11). This evidence concerns the gene TEAD2 and neoplasm.